Cancer Vaccine; Cancer vaccines use high molecular weight stress proteins
Posted on: Thursday, 26 February 2004, 06:00 CST
2004 MAR 5 - (NewsRx.com & NewsRx.net) -- Scientists are developing cancer vaccines using autologous and recombinant high molecular weight stress proteins.
According to published research from the United States, "High molecular weight heat shock proteins (HSPs), hsp110 and grp170, derived from cancer cells have been previously shown to elicit tumor- specific immunity. This phenomenon is attributed to the antigenic peptides associated with the HSPs. Based on the unique chaperoning properties of these HSPs, a new vaccination strategy has been recently developed to elicit antigen-specific antitumor immunity."
"This approach utilizes tumor-associated antigens naturally complexed to these highly efficient molecular chaperones under heat shock conditions," said Xiang-Yang Wang and colleagues at Roswell Park Cancer Institute. "This chapter focuses on the methodologies of these two vaccine strategies: purification of hsp 110 and grp 170 from tumor tissue or cell lines, and generation and characterization of in vitro HSP-antigen complexes by heat shock using recombinant HSPs derived from a baculovirus protein expression system."
Wang and associates published their findings in Methods (Development of cancer vaccines using autologous and recombinant high molecular weight stress proteins. Methods, 2004;32(1):13-20).
Additional information can be obtained by contacting Xiang-Yang Wang, Department of Molecular and Cellular Biophysics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA. E-mail: Xiang- yang.Wang@roswellpark.org.
The publisher of the journal Methods can be contacted at: Academic Press Inc., Elsevier Science, 525 B Street, Suite 1900, San Diego, CA 92101-4495, USA.
The information in this article comes under the major subject areas of Cancer Vaccine, Vaccine Development, Immunology, Immunotherapy, Oncology, and Proteomics.
This article was prepared by Drug Week editors from staff and other reports. Copyright 2004, Drug Week via NewsRx.com & NewsRx.net.
Related Articles
- Data Presented at Cancer Molecular Markers Meeting Suggests Clinical Benefit for Integrating New Molecular Tests
- Targeted Molecular Diagnostics Launches PhosphoGuard(TM) -- a Preservative for Phosphorylated Proteins
- Epigenomics AG: PITX2 Prostate Cancer Molecular Classification Test Successfully Transferred to Affymetrix Diagnostic Platform
- Effective Vaccination Method Discovered
- AlphaVax Gets Patent on Vaccine Method
- Controversial Cancer Preventive Comes Up for FDA Approval: Vaccine Protects Women From Cervical Disease, but Some Say It's Unneeded.
- Fox Chase Cancer Center Study Shows That Inhibitors of Fibroblast Activation Protein (FAP) Attenuate Tumor Growth in Mice
- Updates on MCC Phase III Bladder Cancer Study and E. Coli O157:H7 Cattle Vaccine Regulatory Progress
- Bruker Daltonics Introduces New MALDI Molecular Imager(TM) for In-Vitro Imaging of Protein Biomarkers in Tissue Sections and Cell Clusters
- Novavax, PacificGMP Join on Vaccine Method
 |
 |
User Comments (0)
RSS Feeds